Ronac Mamtani, MD, MSCE
Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Attending Physician, Hematology-Oncology, Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd
Philadelphia, PA 19147
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd
Philadelphia, PA 19147
Office: 2156627606
Fax: (215) 349-8551
Fax: (215) 349-8551
Email:
ronac.mamtani@uphs.upenn.edu
ronac.mamtani@uphs.upenn.edu
Education:
BS
Cornell University, 2002.
MD (Internal Medicine)
Stony Brook School of Medicine, 2006.
MS (Clinical Epidemiology)
University of Pennsylvania , 2012.
Permanent linkBS
Cornell University, 2002.
MD (Internal Medicine)
Stony Brook School of Medicine, 2006.
MS (Clinical Epidemiology)
University of Pennsylvania , 2012.
Selected Publications
Shah M, Mamtani R, Marmarelis ME, Hennessy S: Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90. Clin Lung Cancer 24(3), May 2023.Vader DT, Mamtani R, Li Y, Griffith SD, Calip GS, Hubbard RA.: Inverse Probability of Treatment Weighting and Confounder Missingness in Electronic Health Record-based Analyses: A Comparison of Approaches Using Plasmode Simulation. Epidemiology Page: doi: 10.1097/EDE.0000000000001618, April 2023.
Mamtani R, Zhang H, Parikh RB, Patel K, Li H, Imai K, Hubbard RA: Uptake of Maintenance Immunotherapy and Changes in Upstream Treatment Selection Among Patients With Urothelial Cancer. JAMA Netw Open 6(4), April 2023.
Brown TJ, Mamtani R, Gimotty PA, Karasic TB, Yang YX: Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis. J Cancer Res Clin Oncol 149(6), Mar 2023.
Parikh RB, Hubbard RA, Wang E, Royce TJ, Cohen AB, Clark AS, Mamtani R: Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval. JAMA Oncol Page: doi: 10.1001/jamaoncol.2022.7770, Feb 2023.
Herrera CD, Guerra CE, Narayan V, Guzzo TJ, Mamtani R, Lee DJ, Tasian GE, Talwar R: Financial toxicity in prostate cancer survivors: A national cross-sectional assessment of subjective financial burden. Urol Oncol Feb 2023 Notes: DOI: 10.1016/j.urolonc.2022.10.014.
Voruganti T, Soulos PR, Mamtani R, Presley CJ, Gross CP: Association Between Age and Survival Trends in Advanced Non-Small Cell Lung Cancer After Adoption of Immunotherapy. JAMA Oncol Jan 2023 Notes: doi: 10.1001/jamaoncol.2022.690.
Roberson DS, Xia L, Lee DJ, Pierorazio PM, Malkowicz SB, Mamtani R, Guzzo TJ, Bivalacqua TJ.: Comparison of the 'iROC' trial participants to patients with bladder cancer in the United States undergoing radical cystectomy. BJU Int Page: DOI: 10.1111/bju.15954, Dec 2022.
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA.: NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw 23(8), Dec 2022.
Gotschall JW, Major CK, Jacobs LA, Blauch A, Pucci D, Palmer SC, Mamtani R: Salivary cotinine level and treatment response in muscle invasive bladder cancer: A pilot study. BJUI Compass Page: doi: 10.1002/bco2.204, Dec 2022.